BioCentury | Nov 13, 2018
Distillery Therapeutics

Neurology

...published online Oct. 23, 2018 doi:10.1073/pnas.1813205115 CONTACT: Helena Mira, Carlos III Health Institute, Madrid, Spain email: hmira@ibv.csic.es Jaime De Leon Carlos III Health Institute Bone...
BioCentury | Sep 13, 2018
Translation in Brief

New Therapeutic Targets and Biomarkers: August 2018

...element binding protein 4 (CPEB4) Brain levels of CPEB4 splice variants could help diagnose autism Carlos III Health Institute...
BioCentury | Aug 30, 2018
Tools & Techniques

Master of autism

...RNA-binding protein and translational regulator CPEB4. Study leader José Lucas, a research professor at the Carlos III Health Institute...
...effects of a CPEB4-targeted therapy. Companies and Institutions Mentioned Carnegie Institution for Science, Washington D.C. Carlos III Health Institute...
...transcription and developmental regulator (AUTS2) Cytoplasmic polyadenylation element binding protein 4 (CPEB4) Fragile X mental retardation 1 (FMR1) Autism Carlos III Health Institute...
BioCentury | May 16, 2013
Distillery Therapeutics

Indication: Cancer

...N. et al. J. Clin. Invest.; published online May 1, 2013; doi:10.1172/JCI63623 Contact: Pilar Sánchez-Gómez, Carlos III Health Institute...
BioCentury | Jun 2, 2011
Targets & Mechanisms

Getting at the crux of the antigen

...probably in the postfusion conformation" said José Melero, director of the National Microbiology Center at Carlos III Health Institute...
...Published online June 2, 2011 Companies and Institutions Mentioned AstraZeneca plc (LSE:AZN; NYSE:AZN), London, U.K. Carlos III Health Institute...
BioCentury | Jul 22, 2010
Distillery Techniques

Technology: Drug platforms

...et al. J. Clin. Invest.; published online June 14, 2010; doi:10.1172/JCI41628 Contact: Jordi C. Ochando, Carlos III Health Institute...
BioCentury | Jul 22, 2010
Distillery Techniques

Technology: Assays & screens

...et al. J. Clin. Invest.; published online June 14, 2010; doi:10.1172/JCI41628 Contact: Jordi C. Ochando, Carlos III Health Institute...
Items per page:
1 - 7 of 7
BioCentury | Nov 13, 2018
Distillery Therapeutics

Neurology

...published online Oct. 23, 2018 doi:10.1073/pnas.1813205115 CONTACT: Helena Mira, Carlos III Health Institute, Madrid, Spain email: hmira@ibv.csic.es Jaime De Leon Carlos III Health Institute Bone...
BioCentury | Sep 13, 2018
Translation in Brief

New Therapeutic Targets and Biomarkers: August 2018

...element binding protein 4 (CPEB4) Brain levels of CPEB4 splice variants could help diagnose autism Carlos III Health Institute...
BioCentury | Aug 30, 2018
Tools & Techniques

Master of autism

...RNA-binding protein and translational regulator CPEB4. Study leader José Lucas, a research professor at the Carlos III Health Institute...
...effects of a CPEB4-targeted therapy. Companies and Institutions Mentioned Carnegie Institution for Science, Washington D.C. Carlos III Health Institute...
...transcription and developmental regulator (AUTS2) Cytoplasmic polyadenylation element binding protein 4 (CPEB4) Fragile X mental retardation 1 (FMR1) Autism Carlos III Health Institute...
BioCentury | May 16, 2013
Distillery Therapeutics

Indication: Cancer

...N. et al. J. Clin. Invest.; published online May 1, 2013; doi:10.1172/JCI63623 Contact: Pilar Sánchez-Gómez, Carlos III Health Institute...
BioCentury | Jun 2, 2011
Targets & Mechanisms

Getting at the crux of the antigen

...probably in the postfusion conformation" said José Melero, director of the National Microbiology Center at Carlos III Health Institute...
...Published online June 2, 2011 Companies and Institutions Mentioned AstraZeneca plc (LSE:AZN; NYSE:AZN), London, U.K. Carlos III Health Institute...
BioCentury | Jul 22, 2010
Distillery Techniques

Technology: Drug platforms

...et al. J. Clin. Invest.; published online June 14, 2010; doi:10.1172/JCI41628 Contact: Jordi C. Ochando, Carlos III Health Institute...
BioCentury | Jul 22, 2010
Distillery Techniques

Technology: Assays & screens

...et al. J. Clin. Invest.; published online June 14, 2010; doi:10.1172/JCI41628 Contact: Jordi C. Ochando, Carlos III Health Institute...
Items per page:
1 - 7 of 7